Publications
Key Presentations
-
Emerging Immune Therapeutics Targeting Glioma-mediated Immune Suppression
Amy Heimberger, M.D., presentation at the European Association of Neuro-Oncology meeting, 2012
-
Novel Murine Models of Immune Competent Spontaneously-arising Heterogeneous Gliomas for Evaluating the New Classes of Chemoimmunotherapeutics
Ling-Yuan Kong, M.D. Ph.D, presentation at the Society of Neuro-Oncology meeting, 2010
-
Glioma Cancer Stem Cells Mediate Immune Suppression that Can be Reversed with STAT3 Blockade
Jun Wei, M.D., Ph.D, presentation at the Society of Neuro-Oncology meeting, 2009
-
Tumor-Specific Peptide Vaccination in Newly Diagnosed Patients with GBM
Amy Heimberger, M.D., presentation at the American Society of Clinical Oncology meeting, 2006
Notable Publications
-
Clinical Cancer Research
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors
Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH
-
Clinical Cancer Research
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients
Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K
-
Neuro-Oncology
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses
Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB
-
Cancer Research
A novel small molecule inhibitor of STAT3 reverses immune tolerance in malignant glioma patients
Hussain SF, Kong L-Y, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB
-
Clinical Cancer Research
A novel inhibitor of STAT3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells
Kong L-Y, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer Jr GE, Sampson JH, Priebe W, Heimberger AB
-
Clinical Cancer Research
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas
Heimberger AB, Reina-Ortiz C, Yang DS, Sun W, Abou-Ghazal M, Qiao W, Hiraoka N, Fuller GN
-
Clinical Cancer Research
The incidence, correlation with tumor infiltrating inflammation, and prognosis of p-STAT3 expression in human gliomas
Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong L-K, Fuller GN, Hiraoka N, Priebe W, Sawaya R, Heimberger AB
-
Clinical Cancer Research
Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immune therapeutic response
Kong LY, Wu A, Doucette T, Wei J, Priebe W, Fuller G, Qiao W, Sawaya R, Rao G, Heimberger AB
-
Neuro-Oncology
Glioma cancer stem cells induce immunosuppressive macrophages/microglia
Wu A, Wei J, Kong LY, Wang Y, Priebe W, Sawaya R, Heimberger AB
-
Journal of Clinical Oncology
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III (EGFRvIII) peptide vaccination in patients with newly-diagnosed glioblastoma (GBM)
Heimberger AB*, Sampson JH*, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE II, McLendon RL, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh J, Bigner DD (*Co-lead authors)
-
Molecular Cancer Therapeutics
Glioblastoma cancer-initiating cells inhibit T cell proliferation and effector responses by the STAT3 pathway
Wei J, Barr J, Kong L-Y, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, Sawaya R, Lang FF, Heimberger AB
-
Neuro-Oncology
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon II JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh J, Bigner DD, Heimberger AB
-
Oncotarget
Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma
de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, Qiao W, Heimberger AB
-
Neuro-Oncology
Signal Transducer and Activator of Transcription 3 Promotes Angiogenesis and Drives Malignant Progression in Glioma
Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, Aldape K, Priebe W, Bogler O, Heimberger AB, Rao G
-
Cancer Immunology Research
Immune heterogeneity of glioblastoma subtypes: Extrapolation from the cancer genome atlas
Doucette TA, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M, Heimberger AB
-
Cancer Research
miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma
Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, Yang Y, McEnery K, Jethwa K, Gjyshi O, Qiao W, Levine NB, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger AB
-
Journal of the National Cancer Institute
Effect of miR-142-3p inhibits the M2 macrophage and exerts therapeutic efficacy against murine glioblastoma
Xu S, Wei J, Wang F, Kong LY, Ling XY, Doucette T, Yang Y, Yaghi N, Qiao W, Li XG, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger AB
-
Cancer Immunology Research
Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy
Schrand B, Berezhnoy A, Brenneman R, Williams A, Levay A, Kong LY, Rao G, Zhou S, Heimberger AB, Gilboa E
-
Neuro-Oncology
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JH
-
Journal of the National Cancer Institute
FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas
Yan J, Kong LY, Hu J, Gabrusiewicz K, Dibra D, Xia X, Heimberger AB, Li S
-
Neuro-Oncology
PD-L1 expression and prognostic impact in glioblastoma
Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB
-
JCI Insight
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype
Konrad Gabrusiewicz, Benjamin Rodriguez, Jun Wei, Yuuri Hashimoto, Luke M. Healy, Sourindra N. Maiti, Ginu Thomas, Shouhao Zhou, Qianghu Wang, Ahmed Elakkad, Brandon D. Liebelt, Nasser K. Yaghi, Ravesanker Ezhilarasan, Neal Huang, Jeffrey S. Weinberg, Sujit S. Prabhu, Ganesh Rao, Raymond Sawaya, Lauren A. Langford, Janet M. Bruner, Gregory N. Fuller, Amit Bar-Or, Wei Li, Rivka R. Colen, Michael A. Curran, Krishna P. Bhat, Jack P. Antel, Laurence J. Cooper, Erik P. Sulman, and Amy B. Heimberger
-
JCI
Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target
Jun Wei, Anantha Marisetty, Brett Schrand, Konrad Gabrusiewicz, Yuuri Hashimoto, Martina Ott, Zacharia Grami, Ling-Yuan Kong, Xiaoyang Ling, Hillary Caruso, Shouhao Zhou, Y. Alan Wang, Gregory N. Fuller, Jason Huse, Eli Gilboa, Nannan Kang, Xingxu Huang, Roel Verhaak, Shulin Li, and Amy B. Heimberger
-
Nature Communications
FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
Jun Yan, Qingnan Zhao, Konrad Gabrusiewicz, Ling-Yuan Kong, Xueqing Xia, Jian Wang, Martina Ott, Jingda Xu, R. Eric Davis, Longfei Huo, Ganesh Rao, Shao-Cong Sun, Stephanie S. Watowich, Amy B. Heimberger & Shulin Li